Jyothy Labs share news, announcements and annual reports
NSE: JYOTHYLABBSE: 532926Household ProductsSmall Cap
Jyothy Labs Limited · Formerly Jyothy Laboratories · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2007
Last close ₹171.91down ₹3.15 (1.80%)BSE ₹172.05
Share price at the NSE close on 30 Oct 2026. Previous close ₹175.06.
30 Oct: open ₹174.45, high ₹175.10, low ₹171.00
52-week range of traded prices to 30 Oct 2026
₹171.00Low, 30 Oct 2026₹322.75High, 30 Oct 2025
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and buyback. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,313 Cr603rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.23
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.97
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.04%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 20.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,85,76453.8% delivered
Jyothy Labs disputes and clarifications
20 filed, newest first.
Jul 2025
8 Jul · Legal
The exchange asked on 7 Jul 2025
Oct 2024
22 Oct · Legal
The exchange asked on 22 Oct 2024
Apr 2024
26 Apr · Legal
The exchange asked on 25 Apr 2024
Dec 2022
22 Dec · Legal
The exchange asked on 22 Dec 2022
Aug 2022
26 Aug · Legal
The exchange asked on 24 Aug 2022
May 2019
14 May · Legal
Exchange has sought clarification from Jyothy Laboratories Limited with respect to announcement dated 07-May-2019, regarding Change in Director(s) of the company. On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director). The response of the Company is awaited.
May 2018
18 May · Legal
Exchange has sought clarification from Jyothy Laboratories Limited with respect to announcement dated 16-May-2018, regarding " Jyothy Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 16, 2018 has recommended a Dividend of 50 Paise (Paise Fifty only) per equity share of Re. 1/- each for the financial year 2017-18 on the proposed expanded capital base (on account of Bonus Issue), which if approved by the shareholders at the ensuing Annual General Meeting, will be paid/ dispatched on or after July 30,2018;". On basis of above the Company is required to clarify following: 1. Details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures. 2. Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any; 3. Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal; 4. Special right/interest/privileges attached to the instrument and changes thereof; 5. Charge/security, if any, created over the assets; 6. Coupon/interest offered, schedule of payment of coupon/interest and principal; 7. Tenure of the instrument - date of allotment and date of maturity; 8. Whether proposed to be listed? If yes, name of the stock exchange(s); The response of the Company is awaited.
Aug 2017
Feb 2017
17 Feb · Legal
The exchange asked on 16 Feb 2017
Oct 2016
26 Oct · Legal
Exchange has sought clarification from Jyothy Laboratories Limited with respect to announcement dated 25-Oct-2016, regarding "Jyothy Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 25, 2016.".On basis of above the Company is required to clarify following:1. Whether proposed to be listed? If yes, name of the stock exchange(s);2. Tenure of the instrument - date of allotment and date of maturity;3. Coupon/interest offered, schedule of payment of coupon/interest and principal;4. Charge/security, if any, created over the assets;5. Special right/interest/privileges attached to the instrument and changes thereof;6. Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal;7. Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any;8. Details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures.The response of the Company is awaited.
Aug 2016
12 Aug · Legal
Exchange has sought clarification from Jyothy Laboratories Limited with respect to an announcement submitted to the Exchange dated August 11, 2016, that the Board of Directors of the Company at its meeting held on August 11, 2016 have Accepted resignation of Mr. Bipin R. Shah as the Independent Director of the Company with immediate effect.On basis of above Company are required to clarify following -1. Reason for resignationThe response of the Company is awaited.
Jun 2016
Jan 2014
Aug 2012
27 Aug · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Jyothy Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Jyothy Laboratories Limited has vide its letter inter-alia stated, "We do not have any information / announcement, which are required to be informed to stock exchange."
Jul 2009
16 Jul · Legal
Jyothy Laboratories Limited has clarified to the Exchange, with reference to a news item that appeared in the newspaper dated July 16, 2009, titled "Jyothy Labs to exit venture with Ekta Kapoor; Open to equity participation with global cos", as follows: "We clarify that Company's Ekta Dhoop Business was not substantial / significant in volume / value and its discontinuance will not have any significant impact on the operations / performance / profitability of the Company".